Three Seasons Wealth LLC reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 69.2% during the 1st quarter, Holdings Channel.com reports. The firm owned 511 shares of the company’s stock after selling 1,146 shares during the quarter. Three Seasons Wealth LLC’s holdings in Medpace were worth $245,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP lifted its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC boosted its stake in Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Invesco Ltd. boosted its stake in Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 19.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after buying an additional 60,883 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on MEDP shares. Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets cut their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their target price for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Mizuho upped their price target on Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $469.50.
Medpace Stock Performance
Shares of MEDP stock opened at $537.92 on Friday. The company has a 50 day moving average price of $475.82 and a 200 day moving average price of $494.45. The stock has a market capitalization of $15.36 billion, a P/E ratio of 33.81, a price-to-earnings-growth ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
